The Value of Specialty Pharmacy for the Management of Hemophilia

• Release Date: October 4, 2017
• Expiration Date: April 30, 2019
• Estimated Time to Complete Activity: 1.0 hour
• Compatible with all modern browsers and mobile devices

EXPERT FACULTY

Steven Pipe, MD Professor of Pediatrics and Pathology Laurence A. Boxer Research Professor of Pediatrics and Communicable Diseases Director, Division of Pediatric Hematology and Oncology Pediatric Medical Director, Hemophilia and Coagulation Disorders Program Director, Special Coagulation Laboratory University of Michigan Click here for biography Michael Zeglinski, RPh Senior Vice President, Specialty Pharmacy OptumRx®/BriovaRx® Click here for biography

TARGET AUDIENCE

• Medical Directors and Pharmacy Directors from health plans, HMOs, integrated health systems, employers, quality organizations, and other managed care organizations (MCOs)
• Managed care-affiliated care team members involved with patient evaluation, education, and follow-up for hemophilia patients including: physicians, pharmacists, and nurses

STATEMENT OF NEED/PROGRAM OVERVIEW
Hemophilia is an expensive chronic condition with total annual costs that can average $250,000 or more for severe patients. Optimal outcomes require a collaborative and coordinated patient experience. The collaborative team can include an insurer, Hemophilia Treatment Center (HTC), and specialty pharmacy. Specialty pharmacy services can support patient adherence to treatment and assist physicians, plans, and employers in meeting clinical and/or financial goals. This symposium features a Specialty Pharmacy Expert and a leading Hematologist.

The program will provide an advanced clinical update and emphasize the need for well-coordinated treatment management, best practices to integrate hemophilia care with payer policies, and the value of having collaboration among all stakeholders. This will be an interactive program designed to engage the faculty and audience to develop solutions for specialty pharmacy professionals to implement within their own setting to improve outcomes for patients with hemophilia.

EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:

• Describe current and evolving strategies for specialty pharmacy providers to facilitate high quality care for members with hemophilia
• Cite the most recent clinical recommendations for the treatment of patients with hemophilia, including prophylactic factor replacement and the role of emerging agents
• Explain hemophilia-related complications associated with inhibitor development and its significant clinical and economic consequences
• Identify processes for specialty pharmacy providers to improve communications and collaborations with Hemophilia Treatment Centers (HTCs)
• Apply methods to enable optimal cost management of factor replacement therapy to be realized by specialty pharmacy providers

ACCREDITATION

Pharmacist Continuing Education

	Accreditation Statement Medical Education Resources, Inc. (MER) is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

Credit Designation
MER designates this continuing education activity for 1.0 contact hours (0.10 CEUs) of the Accreditation Council for Pharmacy Education. Universal Activity Number – 0816-9999-17-101-H01-P.

This activity is certified as Knowledge-based CPE.

DISCLOSURE OF CONFLICTS OF INTEREST
It is the policy of Medical Education Resources, Inc. (MER) to ensure balance, independence, objectivity, and scientific rigor in all of its educational activities. In accordance with this policy, MER identifies conflicts of interest with its instructors, content managers, and other individuals who are in a position to control the content of an activity. Conflicts are resolved by MER to ensure that all scientific research referred to, reported, or used in a continuing education activity conforms to the generally accepted standards of experimental design, data collection, and analysis.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this continuing education activity:

Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer
The content and views presented in this educational activity are those of the authors and do not necessarily reflect those of the National Hemophilia Foundation, Medical Education Resources, Inc., Impact Education, LLC, and/or Bayer HealthCare Pharmaceuticals and Shire. The authors have disclosed if there is any discussion of published and/or investigational uses of agents that are not indicated by the FDA in their presentations. The opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of National Hemophilia Foundation, Medical Education Resources, Inc., Impact Education, LLC, and/or Bayer HealthCare Pharmaceuticals and Shire. Before prescribing any medicine, primary references and full prescribing information should be consulted. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. The information presented in this activity is not meant to serve as a guideline for patient management.

METHOD OF PARTICIPATION AND REQUEST FOR CREDIT
There are no fees for participating and receiving CME/CE credit for this activity. During the period October 4, 2017 through April 30, 2019, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) successfully complete the post-test with a score of 70% or better; 4) and complete the evaluation form. Upon completion of the full CME/CE activity, your certificate will be made available immediately to download and print.

For Pharmacists: Upon completion of the activity evaluation, you may immediately submit your CPE credit to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

MEDIA
Internet

FEE INFORMATION
There is no fee for this educational activity.